Company intelligence / Profile preview

Nanjing Aureole Pharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Aureole Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative immunotherapies and vaccines. The company focuses on leveraging its proprietary technology platforms to target Toll-like receptors (TLR) and the STING pathway for the treatment of cancer and chronic infectious diseases like Hepatitis B. Aureole is also actively involved in the development of mRNA-based therapeutics and lipid nanoparticle (LNP) delivery systems. Their pipeline includes several small molecule immune modulators and mRNA vaccine candidates designed to stimulate robust immune responses.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculemRNA-based drugsVaccine
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Aureole Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Aureole Pharmaceutical.

Explore the full profile